Scholarlink

<p>Colorectal cancer (CRC), the third-most prevalent and second deadliest cancer, requires new therapeutic strategies due to the significant side effects of current treatments. We investigated the anticancer properties of MakA, a cytotoxin from <i>Vibrio cholerae</i>, administered systemically in a mouse model, with a focus on its impact on the tumor microenvironment (TME) and immune cell infiltration. Our findings demonstrate that MakA administration is non-toxic and does not cause systemic tissue damage. It increases immune cell abundance in the TME, suppresses tumor growth, promotes cancer cell apoptosis, and enhances leukocyte recruitment and activation. Elevated neutrophil and macrophage densities were associated with increased production of pro-inflammatory mediators with anti-neoplastic properties. These findings highlight MakA’s potential as a targeted, less harmful CRC therapy by modulating the TME immune response.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A bacterial toxin as a novel anti-cancer drug modulating the tumor-microenvironment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月1日

查看全文
  • Lingyu Li,
  • Pauline Evain,
  • Michael Timothy Phillips,
  • Maria Lopez Chiloeches,
  • Anna Bergonzini,
  • Teresa Frisan,
  • Sun Nyunt Wai,
  • Saskia Friederike Erttmann

摘要

Colorectal cancer (CRC), the third-most prevalent and second deadliest cancer, requires new therapeutic strategies due to the significant side effects of current treatments. We investigated the anticancer properties of MakA, a cytotoxin from Vibrio cholerae, administered systemically in a mouse model, with a focus on its impact on the tumor microenvironment (TME) and immune cell infiltration. Our findings demonstrate that MakA administration is non-toxic and does not cause systemic tissue damage. It increases immune cell abundance in the TME, suppresses tumor growth, promotes cancer cell apoptosis, and enhances leukocyte recruitment and activation. Elevated neutrophil and macrophage densities were associated with increased production of pro-inflammatory mediators with anti-neoplastic properties. These findings highlight MakA’s potential as a targeted, less harmful CRC therapy by modulating the TME immune response.